Daniel E Furst


Affiliation: University of California
Country: USA


  1. Furst D, Breedveld F, Kalden J, Smolen J, Burmester G, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66 Suppl 3:iii2-22 pubmed
  2. Furst D, Belasco J, Louie J. Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and management. Clin Immunol. 2019;: pubmed publisher
    ..Knowledge of the genetics and inflammatory factors associated with disease pathogenesis can support the targeted development of new biologic therapies and biomarkers for PsA. ..
  3. request reprint
    Furst D, Khanna D, Matucci Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol. 2007;34:1194-200 pubmed
    ..Another Delphi exercise is designed to develop consensus regarding a combined SSc response index to be validated in future RCT. ..
  4. Furst D, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara C. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology (Oxford). 2015;54:2188-97 pubmed publisher
    ..Patients with shorter disease duration achieved better outcomes, highlighting the need for early treatment. No unexpected safety findings were observed. ClinicalTrials.gov, http://www.clinicaltrials.gov, NCT00195650. ..
  5. Bauer E, Lucier J, Furst D. Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2015;15:883-93 pubmed publisher
    ..The data are equivocal in asthma; however, further studies in this disease are justifiable. The safety profile of this drug thus far is not worrisome although longer studies in more patients are needed. ..
  6. Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo J, Cohen N, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55:669-79 pubmed publisher
    ..Biologic agents in sJIA seem safe and comparable with respect to SAE risk in the short term. ..
  7. request reprint
    Braun Moscovici Y, Braun M, Khanna D, Balbir Gurman A, Furst D. What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?. Clin Exp Rheumatol. 2015;33:S117-22 pubmed
    ..For clinical trials, fully validated tests are preferred, although some investigators use partially validated tests (4 tests). Further validation of GI tests in SSc is needed. ..
  8. Khanna D, Furst D, Allanore Y, Bae S, Bodukam V, Clements P, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology (Oxford). 2015;54:144-51 pubmed publisher
    ..Specific outlines for individual organ systems are to be published separately. This general outline should lead to more uniform and higher-quality trials and clearly delineate areas where further research is needed. ..
  9. Furst D, Keystone E, Fleischmann R, Mease P, Breedveld F, Smolen J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010;69 Suppl 1:i2-29 pubmed publisher

More Information


  1. Wu M, Assassi S, Salazar G, Pedroza C, Gorlova O, Chen W, et al. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res Ther. 2016;18:20 pubmed publisher
    ..However, these associations also did not replicate in the validation cohort. Our results add new evidence that SSc and SSc-related ILD are genetically distinct from IIP, although they share phenotypic similarities. ..
  2. Scheiman Elazary A, Duan L, Shourt C, Agrawal H, Ellashof D, Cameron Hay M, et al. The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis. J Rheumatol. 2016;43:512-23 pubmed publisher
    ..Overall adherence rate was 66%. We suggest that readers appraise adherence studies according to the medications evaluated, the validity of the method, and the scales and cutpoints. ..
  3. Doaty S, Agrawal H, Bauer E, Furst D. Infection and Lupus: Which Causes Which?. Curr Rheumatol Rep. 2016;18:13 pubmed publisher
  4. Amarilyo G, Tarp S, Foeldvari I, Cohen N, Pope T, Woo J, et al. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016;46:312-318 pubmed publisher
    ..Overall, biological agents were effective and safe when compared to placebo. Based on these data, other considerations such as price and availability may need to be used to decide among biological agents when treating pJIA patients. ..
  5. Furst D. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327-46 pubmed publisher
    ..Although suggestive, data for abatacept and rituximab are less definitive and longer periods of patient exposure to these agents are needed before an assessment of their risks can be made. ..
  6. Furst D, Keystone E, Braun J, Breedveld F, Burmester G, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2:i2-45 pubmed publisher
  7. Furst D, Keystone E, Braun J, Breedveld F, Burmester G, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70 Suppl 1:i2-36 pubmed publisher
  8. Senftleber N, Nielsen S, Andersen J, Bliddal H, Tarp S, Lauritzen L, et al. Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials. Nutrients. 2017;9: pubmed publisher
    ..17; 95% CI, -0.57-0.24). The evidence for using marine oil to alleviate pain in arthritis patients was overall of low quality, but of moderate quality in rheumatoid arthritis patients. ..
  9. Wang Y, Gargani L, Barskova T, Furst D, Cerinic M. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. Arthritis Res Ther. 2017;19:206 pubmed publisher
    ..Therefore it is important for clinicians to understand the strengths and limitations of LUS in CTD-ILD patients, to maximize its value. ..
  10. Furst D, Kay J, Wasko M, Keystone E, Kavanaugh A, Deodhar A, et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013;52:1845-55 pubmed publisher
    ..To evaluate the effect of golimumab on haemoglobin levels in patients with RA, PsA or AS...
  11. Kafaja S, Clements P, Wilhalme H, Tseng C, Furst D, Kim G, et al. Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2017;: pubmed publisher
    ..Clinical trial registration available at www.clinicaltrials.gov, IDs NCT00004563 and NCT00883129. ..
  12. request reprint
    Furst D. Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:S5-12 pubmed